secwatch.observer — SEC 8-K summary
======================================

Issuer:     PDS Biotechnology Corp (PDSB)
CIK:        0001472091
Form:       8-K
Filed at:   2025-09-18T23:59:59+00:00
Accession:  0001140361-25-035339
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

PDS Biotech reports 29.5-month median OS in low PD-L1 head and neck cancer cohort
--------------------------------------------------------------------------------

- Median overall survival (mOS) of 29.5 months in CPS 1-19 cohort from VERSATILE-002 Phase 2 trial.
- Published mOS for Keytruda monotherapy was 10.8 months; for Keytruda plus chemo 12.3 months.
- Approximately 60% of trial patients (n=32) had low PD-L1 expression, a historically difficult-to-treat subset.
- Data suggests PDS0101 + Keytruda may eliminate need for chemotherapy in this population.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1472091/000114036125035339/0001140361-25-035339-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1472091/000114036125035339/ef20055698_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-25-035339

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer